Comparative Pharmacology
Head-to-head clinical analysis: CHOLEBRINE versus OMNIPAQUE 140.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHOLEBRINE versus OMNIPAQUE 140.
CHOLEBRINE vs OMNIPAQUE 140
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cholebrine is an iodinated contrast agent that attenuates X-rays, improving visualization of anatomical structures during imaging procedures.
Radiopaque contrast agent that attenuates X-rays due to iodine content, enhancing vascular and tissue visualization.
1-2 mCi (37-74 MBq) intravenously as a single dose for hepatobiliary scintigraphy.
Intravascular: 50-200 mL (containing 7.0-28.0 g iodine) per procedure, administered intravenously as a bolus or infusion; dose depends on imaging modality and body region. Intrathecal: 6-15 mL (containing 0.84-2.1 g iodine) administered via lumbar puncture for myelography.
None Documented
None Documented
Terminal elimination half-life is approximately 2-3 hours in adults with normal renal function; prolonged to 6-12 hours in moderate-to-severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life: 1–2 hours; prolonged in renal impairment (up to 30–40 hours in severe dysfunction).
Primarily renal excretion as unchanged drug (70-80%) and glucuronide conjugates (15-20%); biliary/fecal elimination accounts for <5%.
Renal: >95% unchanged via glomerular filtration; biliary/fecal: negligible (<1%).
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent